An activatable, carrier-free, triple-combination nanomedicine for ALK/EGFR-mutant non-small cell lung cancer highly permeable targeted chemotherapy

Zhonglei Wang; Liyan Yang; Yake Li; Shaohua Song; Juan Qu; Rui He; Shanshan Ren; Peiwei Gong

doi:10.1039/D2NJ03231G

You do not have JavaScript enabled. Please enable JavaScript to access the full features of the site or access our non-JavaScript page.

An activatable, carrier-free, triple-combination nanomedicine for ALK/EGFR-mutant non-small cell lung cancer highly permeable targeted chemotherapy†

Zhonglei Wang,

*^ab Liyan Yang,

^c Yake Li,^a Shaohua Song,^a Juan Qu,^a Rui He,^a Shanshan Ren^a and Peiwei Gong

*^ad

Author affiliations

* Corresponding authors

^a School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu, Shandong, China
E-mail: wangzl16@tsinghua.org.cn, gongpeiwei10@mails.ucas.ac.cn

^b School of Pharmaceutical Sciences, Tsinghua University, Beijing, China

^c School of Physics and Physical Engineering, Qufu Normal University, Qufu, Handong, China

^d State Key Laboratory of Solidification Processing, Center of Advanced Lubrication and Seal Materials, Northwestern Polytechnical University, Xi’an, China

Abstract

Highly permeable targeted chemotherapy is highly desired for treating non-small cell lung cancer (NSCLC). In this study, a novel stimulus-responsive, carrier-free, and triple-combination nano-system (identified as UA@CA4-SS-Cer nanoparticles [NPs]) is developed for the systemic treatment of ALK/EGFR dual-mutant NSCLC. This nanomedicine addresses concerns related to low drug loading and inefficient drug permeability and it provides the foundation for developing GSH-sensitive nanoparticles for improved drug delivery.

Download options Please wait...

Supplementary files

Supplementary information PDF (3098K)

Article information

DOI: https://doi.org/10.1039/D2NJ03231G
Article type: Communication
Submitted: 30 Jun 2022
Accepted: 02 Sep 2022
First published: 05 Sep 2022

Download Citation

New J. Chem., 2022,46, 17673-17677

Permissions

Request permissions

An activatable, carrier-free, triple-combination nanomedicine for ALK/EGFR-mutant non-small cell lung cancer highly permeable targeted chemotherapy

Z. Wang, L. Yang, Y. Li, S. Song, J. Qu, R. He, S. Ren and P. Gong, New J. Chem., 2022, 46, 17673 DOI: 10.1039/D2NJ03231G

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Social activity

Fetching data from CrossRef.
This may take some time to load.

New Journal of Chemistry

An activatable, carrier-free, triple-combination nanomedicine for ALK/EGFR-mutant non-small cell lung cancer highly permeable targeted chemotherapy†

Abstract

Supplementary files

Article information

Download Citation

Permissions

An activatable, carrier-free, triple-combination nanomedicine for ALK/EGFR-mutant non-small cell lung cancer highly permeable targeted chemotherapy

Social activity

Search articles by author

Spotlight

Advertisements